Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Endocr J ; 64(11): 1087-1097, 2017 Nov 29.
Artículo en Inglés | MEDLINE | ID: mdl-28867693

RESUMEN

Thyroid peroxidase (TPO) deficiency, caused by biallelic TPO mutations, is a well-established genetic form of congenital hypothyroidism (CH). More than 100 patients have been published, and the patients have been diagnosed mostly in the frame of newborn screening (NBS) programs. Correlation between clinical phenotypes and TPO activity remains unclear. Here, we report clinical and molecular findings of two unrelated TPO mutation-carrying mildly hypothyroid patients. The two patients were born at term after an uneventful pregnancy and delivery, and were NBS negative. They sought medical attention due to goiter at age 8 years. Evaluation of the thyroid showed mild elevation of serum TSH levels, normal or slightly low serum T4 levels, high serum T3 to T4 molar ratio, high serum thyroglobulin levels, and high thyroidal 123I uptake. We performed next-generation sequencing-based genetic screening, and found that one patient was compound heterozygous for two novel TPO mutations (p.Asp224del; c.820-2A>G), and the other was homozygous for a previously known mutation (p.Trp527Cys). In vitro functional analyses using HEK293 cells showed that the two amino acid-altering mutations (p.Asp224del and p.Trp527Cys) caused partial loss of the enzymatic activity. In conclusion, we report that TPO mutations with residual activity are associated with mild TPO deficiency, which is clinically characterized by marked goiter, mild TSH elevation, high serum T3 to T4 molar ratio, and high serum thyroglobulin levels. Our findings illuminate the hitherto under-recognized correlation between clinical phenotypes and residual enzymatic activity among patients with TPO deficiency.


Asunto(s)
Autoantígenos/genética , Autoantígenos/metabolismo , Hipotiroidismo Congénito/genética , Hipotiroidismo Congénito/metabolismo , Yoduro Peroxidasa/deficiencia , Proteínas de Unión a Hierro/genética , Proteínas de Unión a Hierro/metabolismo , Mutación , Niño , Hipotiroidismo Congénito/diagnóstico , Hipotiroidismo Congénito/patología , Análisis Mutacional de ADN , Femenino , Estudios de Asociación Genética , Pruebas Genéticas , Células HEK293 , Humanos , Recién Nacido , Yoduro Peroxidasa/genética , Yoduro Peroxidasa/metabolismo , Masculino , Tamizaje Neonatal , Linaje , Fenotipo , Índice de Severidad de la Enfermedad
2.
Clin Exp Nephrol ; 15(4): 596-601, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21360022

RESUMEN

A 6-year-old girl was admitted to our hospital with proteinuria, hematuria, skin rash and joint pain of the lower limbs. Due to rapid progression of renal insufficiency, hemodialysis and peritoneal dialysis were performed. She was diagnosed with rapidly progressive glomerulonephritis. Kidney biopsy showed severe crescent formation (50% of glomeruli) and no deposition of any immunoglobulins or complements. Serologically, anti-neutrophil cytoplasmic autoantibody (ANCA) was negative not only by ELISA against proteinase-3 and myeloperoxidase-ANCA but also by indirect immunofluorescent assay against cytoplasmic and perinuclear ANCA. Anti-glomerular basement membrane antibody was also negative. In the acute phase, proinflammatory cytokines such as soluble tumor necrosis factor receptor 1 (sTNFR1), soluble interleukin (IL)-2 receptor (sIL2R), IL-6 and chemokine IL-8 were elevated. The patient was diagnosed with ANCA-negative pauci-immune crescentic glomerulonephritis (CrGN). Intensive treatment with methylprednisolone pulse therapy, plasma exchange, and multiple drug therapy including prednisolone and cyclophosphamide resulted in histopathological improvement and complete remission of proteinuria. There was a possibility that sTNFR1, sIL2R, IL-6 and IL-8 might be involved in the initiation and progression of ANCA-negative pauci-immune CrGN, and to remove and suppress these cytokines might be an effective way to treat ANCA-negative pauci-immune CrGN.


Asunto(s)
Glomerulonefritis/inmunología , Anticuerpos Anticitoplasma de Neutrófilos/inmunología , Autoanticuerpos/análisis , Niño , Ciclofosfamida/administración & dosificación , Quimioterapia Combinada , Femenino , Glomerulonefritis/tratamiento farmacológico , Humanos , Metilprednisolona/administración & dosificación , Plasmaféresis , Prednisolona/administración & dosificación , Proteinuria/tratamiento farmacológico , Proteinuria/etiología , Quimioterapia por Pulso
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA